Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
NEW ORLEANS, April 13, 2018 -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until April 25, 2018 to file lead plaintiff applications in securities class action lawsuits against MiMedx Group Inc. (Nasdaq:MDXG), if they purchased the Company’s securities between the expanded period of March 7, 2013 and February 21, 2018, inclusive (the “Class Period”). These actions are pending in the United States District Courts for the Northern District of Georgia and Southern District of New York.
Get Help
MiMedx investors should visit us at https://www.claimsfiler.com/cases/view-mimedx-group-inc-securities-litigation-2 or call to speak to our claim center toll-free at (844) 367-9658.
About the Lawsuit
MiMedx and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On February 20, 2018, MiMedx revealed it postponed its 2017 earnings report and “engaged independent legal and accounting advisors to conduct an internal investigation into current and prior-period matters relating to allegations regarding certain sales and distribution practices.” Then, on February 22, 2018, media reports revealed that MiMedx had “financial ties to more than 20 doctors” that it had not disclosed to the government, which MiMedx claimed was not required.
On this news, the price of MiMedx’s shares plummeted.
About ClaimsFiler
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. ClaimsFiler's team of experts monitor the securities class action landscape and cull information from a variety of sources to ensure comprehensive coverage across a broad range of financial instruments.
To learn more about ClaimsFiler, visit www.claimsfiler.com.
